The FDA on July 7, 2020 approved INQOVI® for adult patients with MyeloDysplastic Syndromes (MDS) including the following:
1) Previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (Refractory Anemia, Refractory Anemia with Ringed Sideroblasts, Refractory Anemia with excess blasts, and Chronic MyeloMonocytic Leukemia [CMML])
2) Intermediate-1, Intermediate-2, and high-risk International Prognostic Scoring System groups.
INQOVI® is a product of Astex Pharmaceuticals, Inc.
